Sero-Conversion of HCV Negative Patients: A European Study on Sero-Conversion of HCV Negative Patients: A European Study On

Zampieron, Alessandra; Jayasekera, Heather; Elseviers, Monique; Lindley, Elizabeth; Vos, J. Y. De; Harrington, Maurice; Ormandy, Paula

doi:10.1111/j.1755-6686.2006.tb00446.x

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We had already published the results of the centre policy investigation (11) and the description of patients with seroconversion during the one-year observation period (12). We had already published the results of the centre policy investigation (11) and the description of patients with seroconversion during the one-year observation period (12).…”

Section: Introductionmentioning

confidence: 99%

“…The Research Board of EDTNA/ERCA undertook a research project investigating the problem of HCV infection in haemodialysis. We had already published the results of the centre policy investigation (11) and the description of patients with seroconversion during the one-year observation period (12). Within the framework of this HCV project, we were also able to obtain a better insight into the prevalence and incidence of HCV infection in the European dialysis population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

European Study on Epidemiology and Management of Hepatitis C Virus (Hcv) Infection in the Haemodialysis Population Part 3: Prevalence and Incidence

et al. 2006

Self Cite

View full text Add to dashboard Cite

An analysis of the literature showed a high prevalence of HCV in the European dialysis population in the nineties. The prevalence was similar in most countries in northern Europe, but infection was more common in France, Italy, Spain, Portugal and Greece (1) and in Eastern European countries (2). The reported prevalence of anti-HCV-positive patients in the EDTA registry was 21% in 1992 and 18% in 1993 (3) ranging from 1% in Finland to 42% in Egypt (4). The incidence of HCV, in new patients starting renal replacement therapy, ranged from 3% to 7% (5,6) and reported seroconversion rates during dialysis treatment varied between 1% (7) and 16% (8) per year.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

European Study on Epidemiology and Management of Hepatitis C Virus (Hcv) Infection in the Haemodialysis Population Part 3: Prevalence and Incidence

et al. 2006

Self Cite

View full text Add to dashboard Cite

show abstract

Epidemiology and risk factors of HCV infection among hemodialysis patients in countries of the Eastern Mediterranean Regional Office of WHO (EMRO): a quantitative review of literature

2010

View full text Add to dashboard Cite

Background Hepatitis C virus infection (HCV) is the major co-morbidity of patients on chronic hemodialysis. There are many scattered and heterogeneous data about this infection in hemodialysis patients living in countries of the Eastern Mediterranean Region Office of WHO (EMRO) and its distribution is unknown in this region. Aims To provide a more comprehensive tabulation of available data on the epidemiological characteristics and risk factors for HCV infection in hemodialysis patients in Iran and other EMRO countries. Methods A systematic review was carried out based on the computerized literature databases. In all, 95% confidence intervals of infection rates were calculated using the approximate normal distribution model. Pooled odds ratios and 95% CIs were calculated by random effects models. The heterogeneity was assessed by either Q or χ 2 statistics and quantified by I 2 .Results We identified 62 studies that fulfilled our inclusion criteria involving 17,846 hemodialysis subjects. A total of 5,704 (32%) patients had positive serology for HCV infection. The prevalence ranged from 6-72% across countries. Pooled HCV seroprevalence was 17% (95% CI 13-20), 63% (95% CI 61-64), 48% (95% CI 45-51), 72% (95% CI 68-76), 23% (95% CI 21-24) in Iran, Saudi Arabia, Egypt, Morocco and Tunisia respectively. Hemodialysis duration OR=7.63 (95% CI 4.64-12.53), transfusion OR=2.06 (95% CI 1.47-2.89) and previous transplantation failure OR=2.66 (95% CI 1.46-4.86) were major risk factors of HCV infection. Age, sex and dialysis session/ week were not associated with infection rate. Conclusion Nearly 32% (95% CI 31-33) of hemodialysis patients in the EMRO countries are infected with HCV. Despite evolution of new strategies to confine HCV transmission among hemodialysis patients, nosocomial transmission is still the major route of HCV infection in these patients in this region.

show abstract

Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey

Sauné

Kamar

Miédougé

et al. 2010

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

This decreased prevalence and incidence emphasizes the importance of adhering to the recommended universal infection-control precautions. Virological follow-up based on detecting anti-HCV antibodies with sensitive, specific new-generation serological tests could be adequate for dialysis units with few HCV infections. However, new infections in haemodialysis units should be identified by determining the HCV RNA status of seronegative patients. Standardized real-time PCR assays, plus pooling serum samples, make this a promising method for large-scale epidemiological studies.

show abstract

Sero-Conversion of HCV Negative Patients: A European Study on Sero-Conversion of HCV Negative Patients: A European Study On

Cited by 4 publications

References 15 publications

European Study on Epidemiology and Management of Hepatitis C Virus (Hcv) Infection in the Haemodialysis Population Part 3: Prevalence and Incidence

European Study on Epidemiology and Management of Hepatitis C Virus (Hcv) Infection in the Haemodialysis Population Part 3: Prevalence and Incidence

Epidemiology and risk factors of HCV infection among hemodialysis patients in countries of the Eastern Mediterranean Regional Office of WHO (EMRO): a quantitative review of literature

Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey

Contact Info

Product

Resources

About